Avelumab
Avelumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Advanced Solid Tumor、Metastatic Cancer、Cutaneous Melanoma、Non-Small Cell Lung Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
21 项
全球在招研究
2 项
已进入 III/IV 期
14 个
开展国家和地区
暂未检索到
中国境内设点
药品与企业信息
研发企业
- Aulos Bioscience, Inc.
- Groupe Hospitalier Pitie-Salpetriere
- Maastricht University Medical Center
- Groupe Oncologie Radiotherapie Tete et Cou
- SWOG Cancer Research Network
- Queen Mary University of London
- Gruppo Oncologico del Nord-Ovest
- Gustave Roussy, Cancer Campus, Grand Paris
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
法国、比利时、荷兰、西班牙、美国、澳大利亚、英国、意大利、丹麦、加拿大、爱尔兰、德国
正在招募患者的 Avelumab 研究
JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors
不适用招募中法国NCT04294771Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
I 期 / II 期招募中比利时荷兰西班牙NCT04954599Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N
II 期招募中法国NCT06640725Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
I 期 / II 期招募中美国澳大利亚NCT05267626Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
III 期招募中美国NCT04510597Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer
II 期招募中法国西班牙英国NCT06892860Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.
II 期招募中意大利NCT06869473European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
I 期 / II 期招募中丹麦法国意大利荷兰NCT02813135Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
II 期招募中美国澳大利亚加拿大爱尔兰NCT05327686DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
II 期招募中德国NCT07110038Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W
II 期招募中LebanonNCT06686381Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line Treatment
I 期 / II 期招募中法国NCT04396223TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma
II 期招募中法国NCT04678362ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
II 期招募中丹麦NCT04341181Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
II 期招募中美国NCT06228066DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.
IV 期招募中意大利NCT06820255International Multicentric Study ARON-1
不适用招募中意大利NCT05287464Montreal Immune-Related Adverse Events (MIRAE) Study
不适用招募中加拿大NCT05139706Impact of Circadian Rhythm on Immunotherapy
II 期招募中美国NCT07224971Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC
II 期招募中South KoreaNCT07225374Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer
II 期招募中荷兰NCT05600127
中国患者怎么争取用上这款药
目前境内暂未检索到设点，下面几条途径是更现实的选择，每条都有详细的中文做法。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。